

AMENDMENTS TO THE CLAIMS

In the claims:

Please enter the following amendments without prejudice or disclaimer. This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended): A method for providing dopamine or a dopamine precursor to a dopamine deficient prefrontal cortex of a subject ~~with schizophrenia~~ exhibiting negative symptoms of schizophrenia or cognitive defects associated with schizophrenia, comprising administering a cell/support complex to the prefrontal cortex of the subject's brain, wherein said cell/support complex comprises cells adhered to a support matrix, wherein said cells produce dopamine or a dopamine precursor,

wherein the cells are selected from the group consisting of retinal pigment epithelial cells, and chromaffin cells, ~~cells of neural origin, paraneural cells, and cells derived from the adrenal medulla,~~ and

wherein said support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

2. (original): The method of claim 1, wherein said cell/support complex is administered to the subject by injection.

3. (original): The method of claim 1, wherein said cell/support complex is administered to the subject by implantation.

4. (canceled)

5. (previously presented): The method of claim 1, wherein said support matrix is gelatin or modified gelatin.

6. (previously presented): The method of claim 5 wherein said support matrix is crosslinked gelatin.

7-8. (canceled)

9. (previously presented): The method of claim 1 wherein the cells produce a dopamine precursor.

10. (previously presented): The method of claim 1 wherein the cells produce dopamine.

11. (previously presented): The method according to claim 1 wherein the cells are retinal pigment epithelium (RPE) cells.

12. (original): The method of claim 1 wherein the subject is a human.

13-18. (canceled)

19. (withdrawn): A method for treating extrapyramidal side effects (EPS) produced by antipsychotic drugs, comprising administering an effective amount of a cell/support complex comprising therapeutic cells to a site in said subject's brain, wherein said cell/support complex comprises therapeutic cells which produce dopamine or a dopamine precursor adherent to a first support matrix, thereby alleviating said symptoms.

20. (withdrawn): The method of claim 19 wherein said EPS is tardive dyskinesia.

21. (withdrawn): The method of claim 20 wherein said cell/support matrix is administered to the striatal area of said subject's brain.

22. (withdrawn): The method of claim 21 wherein said cell/support matrix is administered by injection.

23. (withdrawn): The method of claim 21 wherein said cell/support matrix is administered by implantation.

24. (withdrawn): The method of claim 21 wherein said first support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

25. (withdrawn): The method of claim 24, wherein said first support matrix is gelatin or modified gelatin.

26. (withdrawn): The method of claim 25 wherein said first support matrix is crosslinked gelatin.

27. (withdrawn): The method of claim 21, wherein the therapeutic cells are selected from the group consisting of retinal pigmented epithelial cells, human foreskin fibroblasts, chromaffin cells, cells of neural origin, paraneural cells, cells engineered by somatic cell hybridization, cells derived from the adrenal medulla, and cells that have been genetically engineered to express a biologically active compound.

28. (withdrawn): The method of claim 27 wherein the therapeutic cells produce a dopamine precursor.

29. (withdrawn): The method of claim 27 wherein the cells produce dopamine.

30. (withdrawn): The method according to claim 29 wherein the therapeutic cells are retinal pigmented epithelium (RPE) cells.

31. (withdrawn): The method of claim 21 wherein the subject is a human.

32. (withdrawn): The method of claim 21 wherein said cell/support complex further comprises protective cells.

33. (withdrawn): The method of claim 32 wherein said cell/support complex further comprises support cells.

34. (withdrawn): The method of claim 21 wherein said cell/support complex further comprises protective cells adherent to a second support matrix.

35. (withdrawn): The method of claim 34 wherein said cell/support complex further comprises support cells adherent to a third support matrix.

36. (withdrawn): A method for improving cognitive deficits associated with schizophrenia, comprising administering an effective amount of a cell/support complex comprising therapeutic cells to a site in said subject's brain, wherein said cell/support complex comprises therapeutic cells which produce dopamine or a dopamine precursor adherent to a first support matrix, thereby alleviating said cognitive deficits.

37-43. (canceled)

44. (previously presented): The method of claim 1 wherein the cell/support complex is administered to the dorsolateral prefrontal cortex of the subject's brain.